Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases

被引：13

作者：

Cioccio, Joseph ^{[1
]}

Claxton, David ^{[1
]}

机构：

[1] Penn State Hershey Med Ctr, Dept Med, Hershey, PA USA

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2019年 / 28卷 / 04期

关键词：

Acute myeloid leukemia; FLT3; targeted therapy; tyrosine kinase; INTERNAL TANDEM DUPLICATION; RISK MYELODYSPLASTIC SYNDROME; C-KIT; FLT3; INHIBITOR; PHASE I/II; IN-VITRO; PROGNOSTIC RELEVANCE; GENE-MUTATIONS; INTENSIVE CHEMOTHERAPY; OLDER PATIENTS;

D O I：

10.1080/13543784.2019.1584610

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Tyrosine kinases (TKs) drive cell survival and proliferation in many normal and malignant cell types. TKs are frequently mutated in acute myeloid leukemia (AML) and hence are increasingly targeted. The management of AML has dramatically improved because of TKI-targeted treatment.Areas Covered: This review provides a biological background for TK inhibitors (TKIs) in AML and reviews their use in the clinic. TK expression and mutation in AML are explored with a focus on TKs associated with specific AML subsets and treatment outcomes. TKIs that specifically target FLT3, c-Kit, and Jak2 are discussed. TKI targeting of specific genes mutated in individual cases and general untargeted' use of these agents are highlighted. Lastly, the mechanisms TKI drug resistance in AML are explored.Expert Opinion: The use of TKIs in the clinic is improving outcomes for many patients. An improved understanding of tyrosine kinase biology and the expanding use of TKIs are likely to dramatically improve outcomes in the coming decade. TKIs and other targeted agents could gradually supplant the use of cytotoxic chemotherapy for AML.

引用

页码：337 / 349

页数：13

共 118 条

[61] Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors [J].

Levis, Mark ;

Brown, Patrick ;

Smith, B. Douglas ;

Stine, Adam ;

Pham, Rosalyn ;

Stone, Richard ;

DeAngelo, Daniel ;

Galinsky, Ilene ;

Giles, Frank ;

Estey, Elihu ;

Kantarjian, Hagop ;

Cohen, Pamela ;

Wang, Yanfeng ;

Roesel, Johannes ;

Karp, Judith E. ;

Small, Donald .

BLOOD, 2006, 108 (10) :3477-3483

[62] Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse [J].

Levis, Mark ;

Ravandi, Farhad ;

Wang, Eunice S. ;

Baer, Maria R. ;

Perl, Alexander ;

Coutre, Steven ;

Erba, Harry ;

Stuart, Robert K. ;

Baccarani, Michele ;

Cripe, Larry D. ;

Tallman, Martin S. ;

Meloni, Giovanna ;

Godley, Lucy A. ;

Langston, Amelia A. ;

Amadori, Sergio ;

Lewis, Ian D. ;

Nagler, Arnon ;

Stone, Richard ;

Yee, Karen ;

Advani, Anjali ;

Douer, Dan ;

Wiktor-Jedrzejczak, W. ;

Juliusson, Gunnar ;

Litzow, Mark R. ;

Petersdorf, Stephen ;

Sanz, Miguel ;

Kantarjian, Hagop M. ;

Sato, Takashi ;

Tremmel, Lothar ;

Bensen-Kennedy, Debra M. ;

Small, Donald ;

Smith, B. Douglas .

BLOOD, 2011, 117 (12) :3294-3301

[63] Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia [J].

Ley, Timothy J. ;

Miller, Christopher ;

Ding, Li ;

Raphael, Benjamin J. ;

Mungall, Andrew J. ;

Robertson, A. Gordon ;

Hoadley, Katherine ;

Triche, Timothy J., Jr. ;

Laird, Peter W. ;

Baty, Jack D. ;

Fulton, Lucinda L. ;

Fulton, Robert ;

Heath, Sharon E. ;

Kalicki-Veizer, Joelle ;

Kandoth, Cyriac ;

Klco, Jeffery M. ;

Koboldt, Daniel C. ;

Kanchi, Krishna-Latha ;

Kulkarni, Shashikant ;

Lamprecht, Tamara L. ;

Larson, David E. ;

Lin, Ling ;

Lu, Charles ;

McLellan, Michael D. ;

McMichael, Joshua F. ;

Payton, Jacqueline ;

Schmidt, Heather ;

Spencer, David H. ;

Tomasson, Michael H. ;

Wallis, John W. ;

Wartman, Lukas D. ;

Watson, Mark A. ;

Welch, John ;

Wendl, Michael C. ;

Ally, Adrian ;

Balasundaram, Miruna ;

Birol, Inanc ;

Butterfield, Yaron ;

Chiu, Readman ;

Chu, Andy ;

Chuah, Eric ;

Chun, Hye-Jung ;

Corbett, Richard ;

Dhalla, Noreen ;

Guin, Ranabir ;

He, An ;

Hirst, Carrie ;

Hirst, Martin ;

Holt, Robert A. ;

Jones, Steven .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (22) :2059-2074

[64] The C-Kit Receptor-Mediated Signal Transduction and Tumor-Related Diseases [J].

Liang, Jing ;

Wu, Yan-Ling ;

Chen, Bing-Jia ;

Zhang, Wen ;

Tanaka, Yoshimasa ;

Sugiyama, Hiroshi .

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2013, 9 (05) :435-443

[65] Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells (vol 24, pg 282, 2018) [J].

Mathew, Nimitha R. ;

Baumgartner, Francis ;

Braun, Lukas ;

O'Sullivan, David ;

Thomas, Simone ;

Waterhouse, Miguel ;

Mueller, Tony A. ;

Hanke, Kathrin ;

Taromi, Sanaz ;

Apostolova, Petya ;

Illert, Anna L. ;

Melchinger, Wolfgang ;

Duquesne, Sandra ;

Schmitt-Graeff, Annette ;

Osswald, Lena ;

Yan, Kai-Li ;

Weber, Arnim ;

Tugues, Sonia ;

Spath, Sabine ;

Pfeifer, Dietmar ;

Follo, Marie ;

Claus, Rainer ;

Lubbert, Michael ;

Rummelt, Christoph ;

Bertz, Hartmut ;

Wasch, Ralph ;

Haag, Johanna ;

Schmidts, Andrea ;

Schultheiss, Michael ;

Bettinger, Dominik ;

Thimme, Robert ;

Ullrich, Evelyn ;

Tanriver, Yakup ;

Vuong, Giang Lam ;

Arnold, Renate ;

Hemmati, Philipp ;

Wolf, Dominik ;

Ditschkowski, Markus ;

Jilg, Cordula ;

Wilhelm, Konrad ;

Leiber, Christian ;

Gerull, Sabine ;

Halter, Jorg ;

Lengerke, Claudia ;

Pabst, Thomas ;

Schroeder, Thomas ;

Kobbe, Guido ;

Rosler, Wolf ;

Doostkam, Soroush ;

Meckel, Stephan .

NATURE MEDICINE, 2018, 24 (03) :282-+

[66] Alternatively spliced, truncated GCSF receptor promotes leukemogenic properties and sensitivity to JAK inhibition [J].

Mehta, H. M. ;

Futami, M. ;

Glaubach, T. ;

Lee, D. W. ;

Andolina, J. R. ;

Yang, Q. ;

Whichard, Z. ;

Quinn, M. ;

Lu, H. F. ;

Kao, W. M. ;

Przychodzen, B. ;

Sarkar, C. A. ;

Minella, A. ;

Maciejewski, J. P. ;

Corey, S. J. .

LEUKEMIA, 2014, 28 (05) :1041-1051

[67] Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia [J].

Meshinchi, S ;

Woods, WG ;

Stirewalt, DL ;

Sweetser, DA ;

Buckley, JD ;

Tjoa, TK ;

Bernstein, ID ;

Radich, JP .

BLOOD, 2001, 97 (01) :89-94

[68] High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses [J].

Metzelder, S. K. ;

Schroeder, T. ;

Finck, A. ;

Scholl, S. ;

Fey, M. ;

Goetze, K. ;

Linn, Y. C. ;

Kroeger, M. ;

Reiter, A. ;

Salih, H. R. ;

Heinicke, T. ;

Stuhlmann, R. ;

Mueller, L. ;

Giagounidis, A. ;

Meyer, R. G. ;

Brugger, W. ;

Voehringer, M. ;

Dreger, P. ;

Mori, M. ;

Basara, N. ;

Schaefer-Eckart, K. ;

Schultheis, B. ;

Baldus, C. ;

Neubauer, A. ;

Burchert, A. .

LEUKEMIA, 2012, 26 (11) :2353-2359

[69] Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia [J].

Metzeler, Klaus H. ;

Herold, Tobias ;

Rothenberg-Thurley, Maja ;

Amler, Susanne ;

Sauerland, Maria C. ;

Gorlich, Dennis ;

Schneider, Stephanie ;

Konstandin, Nikola P. ;

Dufour, Annika ;

Braundl, Kathrin ;

Ksienzyk, Bianka ;

Zellmeier, Evelyn ;

Hartmann, Luise ;

Greif, Philipp A. ;

Fiegl, Michael ;

Subklewe, Marion ;

Bohlander, Stefan K. ;

Krug, Utz ;

Faldum, Andreas ;

Berdel, Wolfgang E. ;

Wormann, Bernhard ;

Buchner, Thomas ;

Hiddemann, Wolfgang ;

Braess, Jan ;

Spiekermann, Karsten .

BLOOD, 2016, 128 (05) :686-698

[70] Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways [J].

Mizuki, M ;

Fenski, R ;

Halfter, H ;

Matsumura, I ;

Schmidt, R ;

Müller, C ;

Grüning, R ;

Kratz-Abers, K ;

Serve, S ;

Steur, C ;

Büchner, T ;

Kienast, J ;

Kanakura, Y ;

Berdel, WE ;

Serve, H .

BLOOD, 2000, 96 (12) :3907-3914

← 2 3 4 5 6 7 8 9 10 11 →